June 18, 2021
Business News

Lineage Reports First Quarter 2021 Financial Results and Highlights Significant Progress With All Three Clinical Programs


CARLSBAD, Calif.–()–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the first quarter 2021. Lineage will host a conference call today at 4:30 p.m. Eastern Time to discuss its first quarter 2021 financial results and to provide a business update.

“Lineage reported significant operational progress with each of its three clinical programs during the first quarter and beyond, delivering not only continued positive clinical results with OpRegen for the treatment of dry-AMD with GA, but also validating partnerships to support our OPC1 and VAC…



Click here to view the original article.

Related Posts

You might also like ...

Sema4 Appoints Andrew Kasarskis, Health Data Expert and Precision Medicine Scientist, as Chief Data Officer
Dan Stahlschmidt Joins Academy Securities as Managing Director, Head of Equity Capital Markets
AON Splash Image
eCommerce Funding and Payments Leader Payability Hires VP of Growth Marketing